Mesothelin is upregulated in the bone marrow of one-third of pediatric AML patients and known for its oncogenic properties in solid tumors, including pancreatic and ovarian cancer [15,19,20,22,42]. This evidence concerns the gene MSLN and acute myeloid leukemia.